Larimar Therapeutics, Inc.
LRMR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001374690
In the last 90 days, Larimar Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 163 institutions reported holding it in 13F filings for Q2 2026, worth $291.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:56 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Feb 12, 2024 | Mar 14, 2023 | Feb 28, 2022 |
| Operating expenses | $172.5M | $90.9M | $41.8M | $36.5M | $50.5M |
| Research and development | $154.2M | $73.3M | $27.7M | $24.3M | $38.4M |
| Selling, general and administrative | $18.3M | $17.6M | $14.1M | $12.3M | $12.1M |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| EPS, basic | – | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
| EPS, diluted | – | $-1.32 | $-0.84 | $-1.37 | $-2.95 |
| Weighted shares, basic | – | 61.3M | 43.9M | 25.8M | 17.2M |
| Weighted shares, diluted | – | 61.3M | 43.9M | 25.8M | 17.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Feb 12, 2024 | Mar 14, 2023 | Feb 28, 2022 |
| Cash and equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M |
| Total current assets | $142.0M | $195.3M | $90.2M | $120.7M | $72.2M |
| Property, plant and equipment | $622.0K | $881.0K | $684.0K | $831.0K | $1.05M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Accounts payable | $5.22M | $2.42M | $1.28M | $1.69M | $1.66M |
| Total current liabilities | $64.8M | $24.4M | $9.51M | $10.7M | $8.85M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Shareholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 24, 2025 | Feb 12, 2024 | Mar 14, 2023 | Feb 28, 2022 |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Capital expenditures | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Stock-based compensation | $7.00M | $8.80M | $7.62M | $6.62M | $5.47M |
| Investing cash flow | $100.3M | -$85.4M | $33.4M | -$91.0M | $24.2M |
| Financing cash flow | $65.1M | $161.9M | $30.0K | $75.3M | $19.9M |
| Net change in cash | $52.2M | $5.74M | -$76.0K | -$43.3M | $1.95M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 2, 2026 | 103.9M | +21.4% | SEC |
| May 12, 2026 | 103.9M | +62.2% | SEC |
| Mar 17, 2026 | 103.9M | +62.2% | SEC |
| Nov 3, 2025 | 85.6M | +34.1% | SEC |
| Aug 12, 2025 | 85.6M | +34.1% | SEC |
| Apr 27, 2025 | 64.0M | +0.4% | SEC |
| Mar 20, 2025 | 64.0M | +0.4% | SEC |
| Oct 28, 2024 | 63.8M | +45.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.